La lecture en ligne est gratuite
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
Télécharger Lire

Cytocell Ltd Introduces New ROS1 Genetic Test for Non-Small-Cell Lung Cancer

2 pages

Cytocell Ltd Introduces New ROS1 Genetic Test for Non-Small- Cell Lung Cancer PR Newswire CAMBRIDGE, England, October 2, 2012 CAMBRIDGE, England, October 2, 2012 /PRNewswire/ -- Cytocell Ltd.

Publié par :
Ajouté le : 09 octobre 2012
Lecture(s) : 15
Signaler un abus
Cytocell Ltd Introduces New ROS1 Genetic
Test for Non-Small-Cell Lung Cancer
PR Newswire
CAMBRIDGE, England, October 2, 2012
October 2, 2012
/PRNewswire/ --
Cytocell Ltd. today announced the availability of a new molecular cytogenetic
test designed to identify the presence of gene rearrangements associated with
a specific form of non-small-cell lung cancer (NSCLC). These rearrangements in
a gene known as ROS1 (c-ros oncogene 1) have been implicated in the
formation of cancerous tumors in patients with NSCLC.
Lung cancer is the world's leading cause of cancer death with more than 1.6
million new cases diagnosed each year. About 85 percent of lung cancer
patients have the non-small-cell type and are usually diagnosed with advanced
disease with a very low survival rate. ALK gene rearrangements have been
shown to respond to therapies that block the ALK pathway. Over 2 percent of
those patients are thought to have ROS1 gene rearrangements and have been
shown to respond to ALK/MET tyrosine kinase inhibitors such as
(crizotinib). The Cytocell ROS1 Breakapart FISH probe uses
In Situ
Hybridization (FISH) technology to detect rearrangements
of the ROS1 gene on chromosome 6 in band 6q22 in tumors. The new Cytocell
assay will complement the existing Cytocell Pathology range which also includes
the equally important ALK Breakapart FISH probe. It is anticipated that both
FISH probes will be used for research, testing, and to support evaluations of
new therapies for NSCLC.
Dr Martin Lawrie, Managing Director of Cytocell stated, "Understanding the
mechanisms of lung cancer and developing new tests that further increase our
knowledge are key to our strategic focus at Cytocell. Through the utilisation of
Cytocell's BACs collection and the myProbes
customised probe service we
were firstly able to offer this probe to several key researchers before launching
it as a catalogue item."
About Cytocell Ltd.
Cytocell is a leading European developer and manufacturer of FISH probes for
use in both routine cytogenetics and in the analysis and classification of
Cancers. The Company's products are well established in Cytogenetics as the
Company is celebrating its 20
year of supplying them to this market. More
recently, the Company has focused on developing products for Oncology and
now has a catalogue of some 350 products for Cytogenetics, Haematology and
Solid Tumour analysis as well as developing custom FISH probes for customers
with specific interests under the myProbes
brand. Cytocell's products are
available through a well established distributor network, covering more than 60
countries worldwide. Cytocell's FISH probe service is currently proving to be
invaluable to cancer researchers and clinicians worldwide.
Cytocell's news releases and other information are available on the company's
Web site at http://www.cytocell.com.
For further enquiries, please contact:
Stewart Kennedy,
Tel: +44-7860-455527
Sales & Marketing Director